Tesamorelin is the groundbreaking FDA-approved peptide that targets excess abdominal fat in HIV-positive patients with lipodystrophy. Its innovative design maximizes growth hormone release, addressing metabolic challenges and improving body composition effectively.
Mechanism
Tesamorelin activates growth hormone-releasing hormone receptors (GHRH-R) in the pituitary, triggering a cascade that leads to increased natural growth hormone release. This process boosts insulin-like growth factor-1 (IGF-1) levels, facilitating fat breakdown and muscle preservation, all while maintaining healthy metabolic feedback loops.
Research
In clinical trials, Tesamorelin demonstrated a significant 15% reduction in visceral fat after 26 weeks, surpassing the FDA's 8% clinical significance threshold. Ongoing assessment of IGF-1 and glucose levels is vital, given the heightened risk of diabetes observed in nearly half of the patients treated.
Synergies
Maximize Tesamorelin's benefits through tailored lifestyle modifications and complementary therapies. Ben IQ assesses YOUR unique labs and goals to optimize your regimen for enhanced results.
Trade-Offs
While Tesamorelin presents compelling advantages, vigilant monitoring for elevated IGF-1 and glucose levels is essential, especially for those with predisposing factors. Personalization is key; YOUR specific data matters.